Equities

Beijing Biostar Pharmaceuticals Co Ltd

Beijing Biostar Pharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)28.90
  • Today's Change-0.150 / -0.52%
  • Shares traded376.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Beijing Biostar Pharmaceuticals Co Ltd had net income fall 18.15% from a loss of 160.51m to a larger loss of 189.64m despite a 103.03% increase in revenues from 32.82m to 66.64m. An increase in the cost of goods sold as a percentage of sales from 27.24% to 29.73% was a component in the falling net income despite rising revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Beijing Biostar Pharmaceuticals Co Ltd fell by 22.02m. However, Cash Flow from Investing totalled 129.83m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 149.33m for operations while cash used for financing totalled 1.13m.
Cash flow per share--
Price/Cash flow per share--
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in CNYView more

Beijing Biostar Pharmaceuticals Co Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.